Literature DB >> 28225682

Decitabine in TP53-Mutated AML.

John S Welch1, Allegra A Petti1, Timothy J Ley1,2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28225682     DOI： 10.1056/NEJMc1616062

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

1.  Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report.

Authors:  Bingshan Liu; Roshni Narurkar; Madhura Hanmantgad; Wahib Zafar; Yongping Song; Delong Liu
Journal:  Front Med       Date:  2018-05-21       Impact factor: 4.592

Review 2.  Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.

Authors:  Miron Prokocimer; Alina Molchadsky; Varda Rotter
Journal:  Blood       Date:  2017-06-12       Impact factor: 22.113

3.  TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML.

Authors:  Jayakumar Vadakekolathu; Catherine Lai; Stephen Reeder; Sarah E Church; Tressa Hood; Anbarasu Lourdusamy; Michael P Rettig; Ibrahim Aldoss; Anjali S Advani; John Godwin; Matthew J Wieduwilt; Martha Arellano; John Muth; Tung On Yau; Farhad Ravandi; Kendra Sweet; Heidi Altmann; Gemma A Foulds; Friedrich Stölzel; Jan Moritz Middeke; Marilena Ciciarello; Antonio Curti; Peter J M Valk; Bob Löwenberg; Ivana Gojo; Martin Bornhäuser; John F DiPersio; Jan K Davidson-Moncada; Sergio Rutella
Journal:  Blood Adv       Date:  2020-10-27

Review 4.  A precision medicine approach to management of acute myeloid leukemia in older adults.

Authors:  Shristi Upadhyay Banskota; Nabin Khanal; Vijaya Raj Bhatt
Journal:  Curr Opin Oncol       Date:  2020-11       Impact factor: 3.915

5.  Hypomethylating Agent Azacitidine Is Effective in Treating Brain Metastasis Triple-Negative Breast Cancer Through Regulation of DNA Methylation of Keratin 18 Gene.

Authors:  Christopher Butler; Samuel Sprowls; Gabor Szalai; Tasneem Arsiwala; Pushkar Saralkar; Benjamin Straight; Shea Hatcher; Evan Tyree; Michael Yost; William J Kohler; Benjamin Wolff; Emily Putnam; Paul Lockman; Tuoen Liu
Journal:  Transl Oncol       Date:  2020-05-11       Impact factor: 4.243

6.  Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).

Authors:  Thomas Cluzeau; Marie Sebert; Ramy Rahmé; Stefania Cuzzubbo; Jacqueline Lehmann-Che; Isabelle Madelaine; Pierre Peterlin; Blandine Bève; Habiba Attalah; Fatiha Chermat; Elsa Miekoutima; Odile Beyne Rauzy; Christian Recher; Aspasia Stamatoullas; Lise Willems; Emmanuel Raffoux; Céline Berthon; Bruno Quesnel; Michael Loschi; Antoine F Carpentier; David A Sallman; Rami Komrokji; Anouk Walter-Petrich; Sylvie Chevret; Lionel Ades; Pierre Fenaux
Journal:  J Clin Oncol       Date:  2021-02-18       Impact factor: 44.544

Review 7.  Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.

Authors:  Andrea Kuendgen; Catharina Müller-Thomas; Michael Lauseker; Torsten Haferlach; Petra Urbaniak; Thomas Schroeder; Carolin Brings; Michael Wulfert; Manja Meggendorfer; Barbara Hildebrandt; Beate Betz; Brigitte Royer-Pokora; Norbert Gattermann; Rainer Haas; Ulrich Germing; Katharina S Götze
Journal:  Oncotarget       Date:  2018-06-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.